← Back to Screener
CalciMedica, Inc. Common Stock (CALC)
Price$1.06
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-83.10%
Price vs S&P 500 (4W)68.53%
VGM Score51.42
Market Capitalization$16.75M
All Metrics
Book Value / Share (Quarterly)$0.44
P/TBV (Annual)0.53x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.34
Price vs S&P 500 (YTD)-92.07%
EPS (TTM)$-1.29
10-Day Avg Trading Volume0.47M
EPS Excl Extra (TTM)$-1.29
EPS (Annual)$-1.97
ROI (Annual)-95.07%
Cash / Share (Quarterly)$0.52
ROA (Last FY)-217.51%
EBITD / Share (TTM)$-1.43
ROE (5Y Avg)-139.87%
Cash Flow / Share (Annual)$-1.37
P/B Ratio2.74x
P/B Ratio (Quarterly)3.66x
Net Income / Employee (Annual)$-1,847,600
Net Interest Coverage (TTM)-3.41x
ROA (TTM)-139.12%
EPS Incl Extra (Annual)$-1.97
Current Ratio (Annual)3.58x
Quick Ratio (Quarterly)1.55x
3-Month Avg Trading Volume0.95M
52-Week Price Return-36.90%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.14
52-Week High$7.20
EPS Excl Extra (Annual)$-1.97
CapEx CAGR (5Y)-51.28%
26-Week Price Return-75.18%
Quick Ratio (Annual)3.46x
13-Week Price Return60.36%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.61x
Enterprise Value$15.28M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.84
3-Month Return Std Dev117.55%
Net Income / Employee (TTM)$-1,221,500
ROE (Last FY)-95.07%
Net Interest Coverage (Annual)-1.17x
EPS Basic Excl Extra (Annual)$-1.97
Total Debt / Equity (Quarterly)1.39x
EPS Incl Extra (TTM)$-1.29
ROI (TTM)-145.13%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$23.21
Price vs S&P 500 (52W)-61.27%
Year-to-Date Return-83.92%
5-Day Price Return25.89%
EPS Normalized (Annual)$-1.97
ROA (5Y Avg)-142.04%
Month-to-Date Return29.74%
Cash Flow / Share (TTM)$-10.97
EBITD / Share (Annual)$-1.54
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-139.87%
LT Debt / Equity (Quarterly)1.39x
EPS Basic Excl Extra (TTM)$-1.29
P/TBV (Quarterly)1.57x
P/B Ratio (Annual)3.31x
Book Value / Share (Annual)$1.07
Price vs S&P 500 (13W)52.11%
Beta0.86x
Revenue / Share (TTM)$0.00
ROE (TTM)-206.51%
52-Week Low$0.46
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 260.30est. -0.29
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.10
4.10
4.10
4.10
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CALCCalciMedica, Inc. Common Stock | — | — | C | $1.06 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
CalciMedica is a clinical-stage biopharmaceutical company developing treatments for serious inflammatory and immune-mediated diseases. Its lead candidate, Auxora, is a CRAC channel inhibitor designed to reduce inflammation and cellular damage in organs including the pancreas, lungs, and kidneys. Preclinical studies suggest potential therapeutic benefit for conditions driven by inflammatory and immune dysfunction.